Exhibit 99.1 Inogen Announces Second Quarter 2024 Financial Results GOLETA, Calif., – August 6, 2024 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2024. "I am proud of the performance of our team in the first half of 2024. We have made meaningful progress on our strategic initiatives, driving top-line growth and advancing the profile of the business toward ...

Investing in small-cap stocks can be a gateway to high returns, mainly when these companies exhibit strong growth fundamentals and strategic market positioning. Here, the focus is on three stocks to buy under $10. The fundamentals behind these companies may diversify portfolios with high potential. These companies' financial performance and strategic initiatives explain why these small-cap stocks are poised for high gains. Source: Poetra.RH / Shutterstock.com The first one has consistently demonstrated impr ...

The renowned provider of POCs has a market capitalization of $212.4 million. The company projects 50.2% growth for 2024 and expects to witness continued improvements in its business. Inogen's P/S ratio of 0.7X compares favorably with the industry's 3.1X. Downsides The Zacks Consensus Estimate for second-quarter 2024 revenues is pegged at $82.3 million, suggesting a 1.6% decline from the year-ago reported number. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22.9%. DX ...

Inogen, Inc. (INGN) incurred an adjusted loss per share of 45 cents for first-quarter 2024, which was narrower than the adjusted loss per share of 63 cents in the year-ago period. The Zacks Consensus Estimate was pegged at a loss of 76 cents per share.GAAP loss per share for the quarter was 62 cents, narrower than the year-earlier loss of 88 cents per share.Revenues in DetailInogen registered revenues of $78 million for the first quarter, up 8.1% year over year. The figure surpassed the Zacks Consensus Esti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. (Exact name of registrant as specified in its charter) Delaware 33-0989359 (State or other jurisdiction of i ...

Inogen, Inc. (NASDAQ:INGN) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Ryan Peterson - Investor Relations Kevin Smith - President and Chief Executive Officer Mike Bourque - Chief Financial Officer Conference Call Participants Colin Clark - Stifel Margaret Kaczor - William Blair Mike Matson - Needham & Company Operator Welcome to Inogen's First Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. [Operator Instructions] As a reminder ...

Inogen (INGN) reported $78.03 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 8.1%. EPS of -$0.62 for the same period compares to -$0.63 a year ago.The reported revenue represents a surprise of +6.48% over the Zacks Consensus Estimate of $73.28 million. With the consensus EPS estimate being -$0.76, the EPS surprise was +18.42%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

GOLETA, Calif., – May 07, 2024 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2024. "We are pleased to be off to a solid start at Inogen in 2024. Looking forward, we remain focused on positioning the business for revenue growth, improving our operating discipline to drive long-term profitability, and investing in our innovation pipeline to broaden our produ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer ...

Inogen, Inc. (NASDAQ:INGN) Q4 2023 Earnings Conference Call February 27, 2024 5:00 PM ET Company Participants Marissa Bych - IR Gilmartin Group Kevin Smith - President and CEO Mike Sergesketter - Interim CFO Conference Call Participants Robbie Marcus – J.P. Morgan Margaret Kaczor Andrew - William Blair Mike Matson - Needham & Company Mathew Blackman - Stifel Operator Greetings, and welcome to the Inogen 2023 Fourth Quarter Financial Results Conference Call. [Operator Instructions] As a reminder, this confer ...